[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1766050A1 - Systeme de dosage utilisant des oligonucleotides marques - Google Patents

Systeme de dosage utilisant des oligonucleotides marques

Info

Publication number
EP1766050A1
EP1766050A1 EP04752910A EP04752910A EP1766050A1 EP 1766050 A1 EP1766050 A1 EP 1766050A1 EP 04752910 A EP04752910 A EP 04752910A EP 04752910 A EP04752910 A EP 04752910A EP 1766050 A1 EP1766050 A1 EP 1766050A1
Authority
EP
European Patent Office
Prior art keywords
capture
oligonucleotides
detectable labels
solid support
ligands
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04752910A
Other languages
German (de)
English (en)
Other versions
EP1766050A4 (fr
Inventor
Parameswara M. Reddy
Daniel A. Keys
Firdous Farooqui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beckman Coulter Inc
Original Assignee
Beckman Coulter Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beckman Coulter Inc filed Critical Beckman Coulter Inc
Publication of EP1766050A1 publication Critical patent/EP1766050A1/fr
Publication of EP1766050A4 publication Critical patent/EP1766050A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase

Definitions

  • An assay can be performed in a number of ways such as the well-known sandwich technique and competitive technique.
  • a variety of specific biological binding molecules can be labeled with a radioactive element, a fluorophore or a constituent which enters into an enzyme reaction.
  • a sample containing suspected target ligands can be analyzed, and the target ligand or target ligands can be detected quantitatively by forming a complex with a labeled anti-ligand, labeled as indicated above, and measuring the labeled constituent in the complex to determine the quantity of the target ligand.
  • the anti-ligand binds to at least one site on the ligand to form a complex.
  • Ligand or target ligand and “anti-ligand,” as these terms are used herein, refer to antigens, antibodies, binding proteins, haptens, hormone receptors, and other biological molecules that can form a complex.
  • the labeled anti-ligand used to detect and measure the target ligand in the complex is referred to herein as the "detector ligand.”
  • a target ligand, a detector ligand, and a capture ligand are used in the assay.
  • the detector ligand is detected quantitatively in a detector ligand/target ligand complex to determine a quantity of the target ligand present.
  • the capture ligand in this technique is an anti-ligand that binds to the target ligand.
  • the capture ligand and detector ligand typically bind to different sites on the target ligand so that there is no interference between the binding of the detector ligand to the target ligand and the capture ligand to the target ligand.
  • the target ligand binds to the capture ligand to form a first complex.
  • the detector ligand also binds to the target ligand in the complex to form a second complex in the sandwich, and the labeled constituent in the sandwiched ligands is detected quantitatively to deduce the quantity of target ligand present.
  • Detection can be performed by: measuring radioactivity where the detector ligand is radioactive; measuring fluorescent light where there is a fluorescent label on the detector ligand; or spectrophotometrically where an optical density or wavelength change occurs through an enzyme reaction, or through fluorescent quenching. Detection may require separation of the sandwiched ligands from unbound ligands and this is generally done by separating the capture ligand attached or immobilized onto a surface from a solution containing unbound detector ligands. The quantity of target ligand is deduced from the quantity of detector ligand detected, because the two quantities are generally directly proportional to each other in the sandwich technique. Parallel tests against known standards are employed for calibration.
  • the quantity of target ligand can be determined as an inverse proportion using the competitive technique previously mentioned above.
  • the capture ligand is contacted either simultaneously or sequentially with a target ligand and a known, limiting quantity of detector ligand.
  • the quantity of detector-ligand detected in a binary complex with the capture ligand is inversely proportional to the amount of target ligand present.
  • the target ligand and detector ligand bind to the same site or sites in close proximity to each other to create competition.
  • the two techniques discussed above may be represented as follows where C designates the capture ligand, T represents the target ligand, and D represents the detector ligand.
  • the present invention satisfies that need.
  • the present invention provides a system that uses labeled oligonucleotides in assays to provide quality control, standardization, and greater precision in detection.
  • An assay device according to the present invention comprises a solid support and a plurality of capture oligonucleotides, wherein at least a portion of the capture oligonucleotides have detectable labels directly attached thereto immobilized onto the solid support.
  • An assay kit comprises a solid support; a plurality of capture oligonucleotides immobilized onto the solid support; and a plurality of capture ligands attached to complementary oligonucleotides, wherein at least a portion of the complementary oligonucleotides have detectable labels directly attached thereto.
  • the complementary oligonucleotides in this assay device being capable of hybridizing under appropriate conditions to form double stranded nucleic acid duplexes with the capture oligonucleotides.
  • a sandwich assay method for a target ligand according to the present invention includes the step of providing a solid support having a plurality of capture oligonucleotides immobilized on the solid support.
  • Another step is adding to the solid support a plurality of capture ligands attached to complementary oligonucleotides, wherein at least a portion of the complementary oligonucleotides have detectable labels directly attached thereto.
  • Another step is providing conditions suitable for hybridization of the complementary oligonucleotides and the capture oligonucleotides to form double stranded nucleic acid duplexes.
  • Another step is bringing the target ligand in contact with the solid support.
  • Another step is adding a plurality of detector ligands having second detectable labels to the solid support.
  • Another step is detecting the first detectable labels, thereby determining the amount of immobilized capture oligonucleotide.
  • Another step is detecting the second detectable labels, thereby determining the amount of the target ligand.
  • Another sandwich assay method for a target ligand according to the present invention includes the step of providing a solid support having a plurality of capture oligonucleotides immobilized on the solid support, wherein at least a portion of the capture oligonucleotides have detectable labels directly attached thereto. Another step is adding to the solid support a plurality of capture ligands attached to complementary oligonucleotides. Another step is providing conditions suitable for hybridization of the complementary oligonucleotides and the capture oligonucleotides to form double stranded nucleic acid duplexes.
  • a competitive assay method for a target ligand according to the present invention includes the step of providing a solid support having a plurality of capture oligonucleotides immobilized on the solid support.
  • Another step is adding to the solid support a plurality of captures ligands attached to complementary oligonucleotides, wherein at least a portion of the complementary oligonucleotides have first detectable labels directly attached thereto.
  • Another step is providing conditions suitable for hybridization of the complementary oligonucleotides and the capture oligonucleotides to form double stranded nucleic acid duplexes.
  • Another step is adding the target ligand to the solid support, wherein the target ligand competes with the detector ligand in binding to the capture ligand.
  • Another step is adding a plurality of detector ligands having second detectable labels to the solid support.
  • Another step is detecting the first detectable labels, thereby determining the amount of immobilized capture oligonucleotide.
  • Another step is detecting the second detectable labels, thereby determining the amount of the target ligand.
  • Another competitive assay method for a target ligand according to the present invention includes the step of providing a solid support having a plurality of capture oligonucleotides immobilized on the solid support, wherein at least a portion of the capture oligonucleotides have first detectable labels directly attached thereto.
  • Another step is adding to the solid support, a plurality of capture ligands attached to complementary oligonucleotides.
  • Another step is providing conditions suitable for hybridization of the complementary oligonucleotides and the capture oligonucleotides to form double stranded nucleic acid duplexes.
  • Another step is adding the target ligand onto the solid support, wherein the target ligand competes with the detector ligand in binding to the capture ligand.
  • Another step is adding a plurality of detector ligands having second detectable labels onto the solid support.
  • Another step is detecting the first detectable labels, thereby determining the amount of immobilized capture oligonucleotide.
  • Another step is detecting the second detectable labels, thereby determining the amount of the target ligand
  • the assay methods i.e.
  • the first and second detectable labels are fluorophores that use the same excitation light source wavelength.
  • the fluorophores typically have different emission wavelengths.
  • the operator of the assay can use the same excitation light source, and determine the quality of the assay's capture components, labeled oligonucleotides immobilized on the solid support, and the concentration of the target ligand, by independently measuring the emission wavelength of each fluorophore.
  • the steps of detecting the first detectable labels and detecting the second detectable labels are simultaneous.
  • Figure 1 shows label detection using the invention where a CCD camera picture detects and illuminates different concentrations of fluorescent label Cy3 directly attached to 30-base capture oligonucleotides immobilized onto the bottom surface of a microtiter in a printed 3 x 3 array pattern.
  • Figure 2 depicts a sandwich assay of the invention using a plurality of immobilized capture oligonucleotides, wherein at least a portion having directly attached fluorescent label Cy3; an oligonucleotide-tagged antibody, wherein the oligonucleotide is complementary to the capture oligonucleotide; an analyte, and a PBXL-1 tagged detection antibody.
  • Figure 3 depicts a sandwich assay of the invention using immobilized capture oligonucleotides; a Cy3 labeled oligonucleotide-tagged antibody, wherein the oligonucleotide is complementary to the capture oligonucleotide; an analyte; and a PBXL-1 tagged detection antibody.
  • Figure 4 shows label detection in a sandwich assay using IL-8 antigen as the target ligand with the invention where a CCD camera picture detects and illuminates different concentrations of fluorescent label PBXL-1 corresponding to detector ligand bound in complexes on the surface of a microtiter in a printed 3 x 3 array pattern.
  • Figure 5 shows label detection in a sandwich assay using IL-8 antigen as the target ligand with the invention where a CCD camera picture detects and illuminates the fluorescent label Cy5.5 directly attached to capture oligonucleotides immobilized onto a microtiter plate, as shown on the left side of the figure, and concentrations of fluorescent label PBXL-1 in bound IL-8 detector antibodies, as shown on the right side.
  • Figure 6 shows label detection in a sandwich assay using the invention where a CCD camera picture detects and illuminates the fluorescent label Cy5.5 directly attached to complementary oligonucleotides attached to antibodies, as shown on the left side of the figure, and concentrations of fluorescent label PBXL-1 in bound detector antibodies for IL-2, IL-8, IL-12, Interferon-gamma, FGF-basic, and GMCSF antigens, as shown on the right side.
  • Figure 7 depicts a competitive assay of the invention using immobilized complementary oligonucleotides; a Cy3 labeled oligonucleotide-tagged antibody, wherein the oligonucleotide is complementary to the capture oligonucleotide; a target analyte; and a competing PBXL-1 labeled analyte.
  • DESCRIPTION The following discussion describes embodiments of the invention and several variations of these embodiments. This discussion should not be construed, however, as limiting the invention to these particular embodiments. Practitioners skilled in the art will recognize numerous other embodiments as well.
  • the present invention provides a system that uses capture oligonucleotides in assays to provide quality control, standardization, and greater precision in detection of target ligands.
  • capture oligonucleotides also yields efficient and easy manufacturing, and quality control methods that far exceed prior systems in ease of use for manufacturer and consumer.
  • the phrase “directly attached” or “directly attaching” in referring to attaching a label to a capture or complementary oligonucleotide means that the label is attached to the oligonucleotide, and not to a ligand or anti-ligand which can also be attached to the oligonucleotide.
  • capture oligonucleotide means an oligonucleotide immobilized or attached to a solid support which can bind a complementary oligonucleotide attached to a capture ligand.
  • complementary oligonucleotide or "oligonucleotide complementary to a capture oligonucleotide” refers to a nucleotide sequence attached to a capture ligand that hybridizes to the capture oligonucleotide under conditions suitable for hybridization thereby forming double stranded nucleic acid duplexes.
  • detectable labels directly attached to capture oligonucleotides or to complementary oligonucleotides provides important innovations not taught in any of the references discussed in the background section.
  • the invention's use of labeled oligonucleotides is significant.
  • the label is directly attached to the capture oligonucleotide or the complementary oligonucleotide, and can be easily detected by a manufacturer or customer without the need or presence of a capture ligand.
  • This provides an effective method of determining the quality of the assay device.
  • oligonucleotide arrays are more stable than the antibody arrays that can be used as a labeled capture ligand, and oligonucleotides have a longer shelf life. Therefore, a user of the present invention can have a readily available labeled oligonucleotide assay device on the shelf, and an easily verifiable quality control system in place.
  • Another benefit of the present invention is that the proximity and orientation of labels on an oligonucleotide can be more easily and precisely controlled. For example, using directly attached labels on oligonucleotides in the invention bound to a surface, the distance and orientation (and therefore the interaction) of a fluorescent dye to the surface is uniform, and can be easily controlled, resulting in more uniform and consistent fluorescence. In contrast, using labels attached to an antibody without an oligonucleotide as an intermediary link, the distance and orientation of the fluorescent labels to the surface is random, resulting in variable and inconsistent fluorescence (due to interference of the surface with the fluorescence emission). Other important beneficial differences are that: 1.
  • Oligonucleotides can be used to label a variety of classes of molecules, such as antibodies, nucleic acids, lectins, cell-surface receptors, etc.
  • a single array of first (unlabeled) oligonucleotides, complementary to the labeled oligonucleotide-complexes, can be used as a universal substrate to generate a self-assembling array of these different classes of molecules.
  • the fluorescence characteristics of labels may be affected by the secondary and tertiary conformations and structures of different proteins. This risk is minimized or eliminated by labeling through oligonucleotides.
  • a fluorescent label can be attached to either the immobilized capture oligonucleotide or to its complementary oligonucleotide-antibody complex.
  • the invention's use of directly attached labels on oligonucleotides does not interfere with the performance, sensitivity, or dynamic range of detection of the target ligand in an assay, while providing a convenient method to monitor the quality of an array from manufacture throughout the actual assay procedure.
  • the CCD camera picture from Figure 4 shows the invention does not interfere with the performance, sensitivity, or dynamic range of an assay.
  • the CCD camera picture of Figure 4 shows that the concentration of labeled oligonucleotides did not have an appreciable effect on detection of the IL-8 analyte regardless of the concentration of IL-8 analyte. The detection of IL-8 analyte was consistent.
  • columns A-E on the top of the figure correspond to the respective concentrations of Cy3 labeled oligonucleotides from 6 ⁇ M, 4 ⁇ M, 2 ⁇ M, 1 ⁇ M, to 0 ⁇ M.
  • concentration of IL-8 analyte, the target ligand ranged from 0 pg/ml to 1000 pg/ml as identified on the right side of the figure.
  • the intensity of the fluorescent emissions or brightness of the spots correlated to detection of the IL-8 analyte.
  • the protocol for the IL 8 assay shown in Figure 4 is described below: Step I.
  • Solid supports capable of having capture oligonucleotides immobilized onto the surface include, but are not limited to polypropylene, polystyrene, glass, nitrocellulose, polyvinylidene fluoride ("PVDF"), and nylon.
  • the solid supports used in the invention may take different forms such as bead, plate, film, or other structures.
  • Complementary oligonucleotides for the capture oligonucleotides can be directly attached to a variety of different molecules including antigens, antibodies, binding proteins, haptens, hormone receptors, hormones, lectins, carbohydrates, metabolites, drugs, enzyme substrates, and viral proteins for use in the present invention.
  • Complementary oligonucleotides have been directly attached to antibodies to human IL-lb, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, VEGF, FGF-basic, IFNg, GMCSF, TNF, and used in assays for the invention.
  • the methods for attachment of complementary oligonucleotides to the above antibodies are well known to one of ordinary skill in the art. See e.g. , U.S. Patent No. 5,648,213 (Reddy).
  • conditions must be suitable to permit the complementary oligonucleotides to hybridize to capture oligonucleotides to form nucleic acid duplexes.
  • Capture and complementary oligonucleotides used in the present invention range from about 15 to about 45 base oligonucleotides.
  • the capture and complementary oligonucleotides preferably each have about 20 to about 30 base oligonucleotides.
  • a pair of capture and complementary oligonucleotides can be used to capture a single specific target ligand.
  • a pair of capture and complementary oligonucleotides can be used in a well a microtiter plate to capture a specific target ligand in that well.
  • an array of different capture and complementary oligonucleotide can be used to capture different target ligands.
  • the preferred sequences are selected from a group of pairs that do not have substantial cross hybridization. Preferred pairs include:
  • an array selected from the above different sequences can be used in a well of a microtitier plate when more than one target ligand is captured in the well.
  • detectable labels include but are not limited to fluorophores, radioactive, chemiluminescent, bioluminescent, enzyme, nephelometric, turbidometric, and visible labels.
  • fluorophores examples include but are not limited to rhodamine 110, rhodal, fluorescein, coumarin, and derivatives of rhodamine 110, rhodal, or fluorescein.
  • Cyanine dyes such as Cy2, Cy3, Cy5, Cy5.5, and Cy7.
  • radioactive labels examples include but are not limited to 32 P, 33 P, 35 S, 3 H, and 125 I.
  • chemiluminescent labels examples include but are not limited to acridinium esters, ruthenium complexes, metal complexes, oxalate ester - peroxide combination.
  • enzyme labels that can be used in the invention include but are not limited to alkaline phosphatase, horseradish peroxidase, beta-galactosidase.
  • visible labels that can be used in the invention include but are not limited to thiopeptolides, anthroquinone dyes, nitro blue tetrazolium, ortho-nitrophenol ⁇ -D-galacto-piranoside
  • the same type of labels, discussed above, can also be used on detector ligands.
  • Methods for attachment of detectable labels to oligonucleotides are well known to one of ordinary skill in the arts. For example, such methods are described in Yang and Millar, Methods in Enzymology, Vol. 278, pages 417-444, 1997.
  • the system of the present invention can be used in the creation of assay devices, in quality control in the manufacturing process, in quality control in the customer's laboratory, and as a final quality control during the detection of the target ligand in the assay.
  • An assay device comprises a solid support and a plurality of capture oligonucleotides, wherein at least a portion of the capture oligonucleotides have detectable labels directly attached thereto immobilized onto the solid support.
  • Embodiments of the assay device can include an assay device where: all of the capture oligonucleotides are the same; or all of the detectable labels are the same; or wherein the detectable label is selected from the group consisting of fluorophores, radioactive, chemiluminescent, bioluminescent, enzyme, nephelometric, turbidometric, and visible labels.
  • An assay kit comprises a solid support; a plurality of capture oligonucleotides immobilized onto the solid support; and a plurality of capture ligands attached to complementary oligonucleotides, wherein at least a portion of the complementary oligonucleotides have detectable labels directly attached thereto.
  • the complementary oligonucleotides in this assay device being capable of hybridizing under appropriate conditions to form double stranded nucleic acid duplexes with the capture oligonucleotides.
  • Embodiments of this assay kit can include an assay device where: all of the capture oligonucleotides are the same; or where the capture ligands are antibodies; or wherein all of the detectable labels are the same; or wherein the capture oligonucleotides and complementary oligonucleotides are in the form of double stranded nucleic acid duplexes.
  • a sandwich assay method for a target ligand according to the present invention includes the step of providing a solid support having a plurality of capture oligonucleotides immobilized on the solid support.
  • Another step is adding to the solid support of a plurality of capture ligands attached to complementary oligonucleotides, wherein at least a portion of the complementary oligonucleotides have detectable labels directly attached thereto.
  • Another step is providing conditions suitable for hybridization of the complementary oligonucleotides and the capture oligonucleotides to form double stranded nucleic acid duplexes.
  • Another step is to bring the target ligand in contact with the solid support.
  • Another step is adding a plurality of detector ligands having second detectable labels to the solid support.
  • Another step is detecting the first detectable labels, thereby determining the amount of immobilized capture oligonucleotide.
  • Another step is detecting the second detectable labels, thereby determining the amount of the target ligand.
  • Another sandwich assay method for a target ligand according to the present invention includes the step of providing a solid support having a plurality of capture oligonucleotides immobilized on the solid support, wherein at least a portion of the capture oligonucleotides have detectable labels directly attached thereto. Another step is adding to the solid support a plurality of capture ligands attached to complementary oligonucleotides. Another step is providing conditions suitable for hybridization of the complementary oligonucleotides and the capture oligonucleotides to form double stranded nucleic acid duplexes.
  • Another step is bringing the target ligand in contact with the solid support.
  • Another step is adding a plurality of detector ligands having second detectable labels to the solid support.
  • Another step is detecting the first detectable labels, thereby determining the amount of immobilized capture oligonucleotide.
  • Another step is detecting the second detectable labels, thereby determining the amount of the target ligand.
  • Embodiments of the sandwich assay described can include: wherein the capture ligands and the detector ligands are antibodies; or wherein the capture ligands and the detector ligands are antigens; or wherein the step of detecting the first and second detectable labels is by quantitatively measuring each label; or wherein the step of adding a plurality of detector ligands occurs before the step of providing conditions suitable for hybridization; or wherein the detectable label is selected from the group consisting of fluorophores, radioactive, chemiluminescent, bioluminescent, enzyme, nephelometric, turbidometric, and visible labels.
  • a competitive assay method for a target ligand includes the step of providing a solid support having a plurality of capture oligonucleotides immobilized on the solid support. Another step is adding to the solid support a plurality of capture ligands attached to complementary oligonucleotides, wherein at least a portion of the complementary oligonucleotides have first detectable labels directly attached thereto. Another step is providing conditions suitable for hybridization of the complementary oligonucleotides and the capture oligonucleotides to form double stranded nucleic acid duplexes. Another step is adding the target ligand to the solid support, wherein the target ligand competes with the detector ligand in binding to the capture ligand.
  • Another step is adding a plurality of detector ligands having second detectable labels to the solid support. Another step is detecting the first detectable labels, thereby determining the amount of immobilized capture oligonucleotide. Another step is detecting the second detectable labels, thereby determining the amount of the target ligand.
  • Another competitive assay method for a target ligand according to the present invention includes the step of providing a solid support having a plurality of capture oligonucleotides immobilized on the solid support, wherein at least a portion of the capture oligonucleotides have first detectable labels directly attached thereto. Another step is adding to the solid support, a plurality of capture ligands attached to complementary oligonucleotides.
  • Another step is providing conditions suitable for hybridization of the complementary oligonucleotides and the capture oligonucleotides to form double stranded nucleic acid duplexes.
  • Another step is adding the target ligand onto the solid support, wherein the target ligand competes with the detector ligand in binding to the capture ligand.
  • Another step is adding a plurality of detector ligands having second detectable labels onto the solid support.
  • Another step is detecting the first detectable labels, thereby determining the amount of immobilized capture oligonucleotide.
  • Another step is detecting the second detectable labels, thereby determining the amount of the target ligand.
  • the first and second detectable labels are fluorophores that use the same excitation light source wavelength.
  • the fluorophores typically have different emission wavelengths.
  • the operator of the assay can use the same excitation light source, and determine the quality of the assay's capture components, labeled oligonucleotides immobilized on the solid support, and the concentration of the target ligand, by independently measuring the emission wavelength of each fluorophore.
  • the steps of detecting the first detectable labels and detecting the second detectable labels are simultaneous. Preferred embodiments of sandwich assays of the invention are depicted in Figures 2 and 3.
  • Cy3 labeled oligonucleotides and PBXL-1 labeled detection antibody are the first and second detectable labels, and these respective labels use the same excitation wavelength of 550 nm.
  • the Cy3 label directly attached to the oligonucleotides has an emission wavelength of 575 nm
  • the PBXL-1 label has an emission wavelength of 675 nm. Therefore, when an excitation wavelength of 550 nm is used, detection and measurement of both labels can result because each label has a different emission wavelength.
  • the difference between the embodiments shown in Figures 2 and 3 is which oligonucleotide has the directly attached Cy3 label.
  • Figure 7 depicts a preferred embodiment of a competitive assay of the present invention using immobilized capture oligonucleotides; a Cy3 labeled oligonucleotide-tagged antibody, wherein the oligonucleotide is complementary to the capture oligonucleotide; a target analyte; and a competing PBXL-1 labeled analyte.
  • the detector ligand is called the "competing labeled analyte”
  • the target ligand is called the target analyte.
  • the following pairs of labels can be used: fluorescein and rhodamine; Cy3 and Cy5; PBXL-1 and Cy5.5; and fluorescein and PBXL-1.
  • the assay devices, method of manufacturing, and assays for target ligands can use the same capture oligonucleotides and complementary oligonucleotides or combinations of different capture oligonucleotides and their respective complementary oligonucleotides.
  • One of ordinary skill in the art will know how to prepare a variety of assays, including but not limited to sandwich and competitive assays, according to the present invention. A variety of different permutations of the invention is contemplated, and not meant to be limited by this disclosure.
  • dye phosphoramidite Cy3 purchased from Glen research, Sterling, Virginia was coupled using the standard protocol recommended by the supplier of the reagents.
  • the wells of polypropylene microtiter plates were aminated by radio frequency plasma discharge treatment under an ammonia atmosphere using a Plasma Science Model PS0150 RFPD generator system.
  • the aminated plates were then succinylated by treatment with 0.1 M succinic anhydride in 0.1 M sodium acetate for 20 hrs, followed by 3 washes with 0.1 M sodium acetate and 3 washes with isopropyl alcohol.
  • Succinylated plates were then reacted for 2 hrs with 250 mM triazole in acetonitrile containing 3% triethylamine, followed by 3 washes with acetonitrile.
  • Capture oligonucleotides were chemically coupled to the surface of the activated plates by depositing approximately 10 nl spots of 20 ⁇ M solution of the capture oligonucleotides containing about 0 to about 6 ⁇ M of Cy3-labeled oligonucleotides, onto the bottom surface of a microtiter plate in a 3 x 3 microarray pattern.
  • a Biomek 2000 high-density replicating tool (Beckman Coulter, Fullerton, CA) or a ProSys Gantry System (Cartesian Technologies, Irvine, CA) were used to deposit the spots in microarray s. The plates were incubated 16 hr at room temperature in a humidified chamber.
  • the plates were then 'quenched' by incubating in a 1 % casein solution in carbonate buffer, pH 9.3, for 1 hour to bind to any amino-reactive groups remaining on the plate surface.
  • the plates were then washed with water, followed by a wash with TE buffer (10 mM Tris, pH 7.5, 1 mM EDTA).
  • TE buffer 10 mM Tris, pH 7.5, 1 mM EDTA.
  • the microarrays were illuminated with a 550 nm light source and visualized with a charge coupled device camera ("CCD camera").
  • the CCD camera used was a Photometries CoolSNAP camera (Roper Scientific, Arlington, AZ) mounted with a 575 nm emission filter.
  • Figure 1 shows the CCD camera picture illustrating the emissions from labels of the capture oligonucleotides having concentrations of 6 ⁇ M, 4 ⁇ M, 2 ⁇ M, 1 ⁇ M, and 0 ⁇ M of Cy3- labeled oligonucleotides identified by Columns A, B, C, D, and E respectively.
  • EXAMPLE 2 shows the CCD camera picture illustrating the emissions from labels of the capture oligonucleotides having concentrations of 6 ⁇ M, 4 ⁇ M, 2 ⁇ M, 1 ⁇ M, and 0 ⁇ M of Cy3- labeled oligonucleotides identified by Columns A, B, C, D, and E respectively.
  • the microarrays were illuminated with a 550 nm light source and visualized with a CCD camera.
  • the CCD camera used was a Photometries CoolSNAP camera (Roper Scientific,
  • Example 2 DETECTOR LIGANDS WITH PBXL-1 LABELS, AND IL-8 ANTIGENS
  • the procedure described in Example 1 was used to synthesize and immobilize arrays of capture oligonucleotide with directly attached Cy3 labels onto a microtiter plate.
  • the complementary oligonucleotides were synthesized by the same procedure as the labeled oligonucleotides except that unlabeled nucleotides were used for the terminal base, and attached to the capture antibody.
  • the protocol for the attachment of oligonucleotide to antibody discussed in U.S.
  • the target ligand was IL-8 antigen
  • the capture ligand was an IL-8 antibody conjugated to an oligonucleotide that is complementary to capture oligonucleotides of an immobilized array
  • the detector ligands were IL-8 antibodies labeled with PBXL-1
  • IL-8 antibodies were labeled with PBXL-1 through a biotin-streptavidin interaction by mixing: IL-8 detection antibodies that were covalently coupled to biotin (as supplied by the manufacturer, R & D Systems); and PBXL-1 that was supplied as a streptavidin conjugate supplied by the manufacturer, Martek. 50 ⁇ l of 10 nM of IL-8 antibody conjugated to an oligonucleotide that is complementary to capture oligonucleotides in casein buffer was added to the immobilized capture oligonucleotides.
  • This step was performed under conditions typical for a normal immunoassay binding step (i.e. moderate salt and temperature conditions), partly to protect the structure and integrity of the antibody portion of the conjugate, and partly for ease of use.
  • Concentrations of IL-8 antigen ranging from 1000-0 pg/ml per well in casein buffer were added and reacted at 37°C for 1 hour and washed with wash buffer 3 times.
  • the concentrations of IL-8 antigen used in the assay were: 0 pg/ml, 5 pg/ml, 100 pg/ml, and 1000 pg/ml.
  • Figure 4 shows the CCD camera picture illustrating the emissions from PBXL-1 labels of the bound IL-8 detector antibodies for each concentrations of IL-8 antigen.
  • On the right side of the picture is the IL-8 antigen concentration, and top columns A, B, C, D, and E of the picture respectively correspond to 6 ⁇ M, 4 ⁇ M, 2 ⁇ M, l ⁇ M, and O ⁇ M of Cy3 labeled capture oligonucleotides.
  • Figure 1 shows the CCD camera picture illustrating the emissions from Cy3 labeled capture oligonucleotides from the same plate used in this example.
  • Example 1 A SANDWICH ASSAY USING Cy5.5 LABELED CAPTURE OLIGONUCLEOTIDES, IL- 8 ANTIBODIES CONJUGATED TO COMPLEMENTARY OLIGONUCLEOTIDES, DETECTOR LIGANDS WITH PBXL-1 LABELS, AND IL-8 ANTIGENS
  • the procedure described in Example 1 was used to synthesize and immobilize arrays of capture oligonucleotide with directly attached Cy5.5 label, instead of the Cy3 label used in Example 1, onto a microtiter plate.
  • the complementary oligonucleotides were synthesized by the same method as the labeled oligonucleotides except that unlabeled nucleotides were used for the terminal base, and attached to the capture antibody.
  • the protocol for attachment of complementary oligonucleotide to IL-8 antibody for the IL-8 assay was discussed in U.S. Patent No. 5,648, 213, which is inco ⁇ orated by reference herein, and was used for this example.
  • the target ligand was IL-8 antigen
  • the capture ligand was an IL-8 antibody conjugated to an oligonucleotide that is complementary to capture oligonucleotides of an immobilized array
  • the detector ligands were IL-8 antibodies labeled with PBXL-1 (a fluorescent dye purchased from Martek Biosciences Co ⁇ .; Columbia, Maryland).
  • the detector ligands, IL-8 antibodies were labeled with PBXL-1 -1 through a biotin-streptavidin interaction by mixing: IL-8 detector antibodies that were covalently coupled to biotin (as supplied by the manufacturer, R & D Systems); and PBXL-1 that was supplied as a streptavidin conjugate supplied by the manufacturer, Martek. 50 ⁇ l of 10 nM of IL-8 antibody conjugated to an oligonucleotide that is complementary to capture oligonucleotides in casein buffer was added to the immobilized capture oligonucleotides. This step was performed under conditions typical for a normal immunoassay binding step (i.e.
  • Concentrations of IL-8 antigen ranging from 250-0 pg/ml per well in casein buffer were added and reacted at 37°C for 1 hour and washed with wash buffer 3 times.
  • concentrations of IL-8 antigen used in the assay were: 0 pg/ml, 1 pg/ml, 2 pg/ml, 5 pg/ml, 10 pg/ml, 25 pg/ml, 100 pg/ml, and 250 pg/ml.
  • a different capture and complementary oligonucleotide sequence was used for each of the target ligands tested in this example: IL-2, IL-8, IL-12, Interferon-gamma, FGF-basic, GMCSF antigens, and an internal control antigen, used in this example. Seven different preferred pairs of capture and complementary oligonucleotides were used in this example. The seven pairs were selected from a list of preferred sequence pairs because the sequences do not substantially cross hybridize when used together in an assay. The list of preferred pair was previously identified. D. Immobilization Of Capture Amino Oligonucleotide In A Microarray Onto A Microtiter Plate.
  • the immobilization of capture oligonucleotides onto a microtiter plate as used in this example was the basic procedure described under Example 1 and 3.
  • each of the six different capture oligonucleotides were immobilized at predetermined spots in the microarray to correspond to the specific antigen or target ligand.
  • a different antigen (not one of the six target antigens), chicken ovalbumin, was used as an internal control, and the seventh different capture oligonucleotide was immobilized in three corner positions. This internal control is shown in the picture in Figure 6 as the brightest PBXL-1 emissions at three corner positions in the 0 pg/ml and 2 pg/ml concentrations of the target antigens.
  • the capture ligand used in this example for an IL-8 antigen was an IL-8 antibody.
  • the IL-8 antibody was conjugated to an oligonucleotide that is complementary to its respective capture oligonucleotide in immobilized microarray.
  • the detector ligands for IL-8 antigens were IL-8 antibodies labeled with PBXL-1 (a fluorescent dye purchased from Martek Biosciences Co ⁇ .; Columbia, Maryland).
  • the detector ligands, IL-8 antibodies were labeled with PBXL-1 -1 through a biotin-streptavidin interaction by mixing: IL-8 detector antibodies that were covalently coupled to biotin (as supplied by the manufacturer, R & D Systems); and PBXL-1 that was supplied as a streptavidin conjugate supplied by the manufacturer, Martek.
  • the capture ligands and detector ligands for the remaining antigens were made using the same process described for the IL-8.
  • the respective antibodies for IL-2, IL-12, Interferon-gamma, FGF-basic, and GMCSF were used to create the necessary components of the sandwich.
  • F. IL-8 Assay Protocol Used The basic protocol for the IL 8 assay discussed in Example 4 was used for this example. However, in addition to IL-8 antigen, the following target ligands were also used in this example: IL-2, IL-12, Interferon-gamma, FGF-basic, and GMCSF antigens.
  • the first step in the assay was the immobilization of the capture oligonucleotides in a predetermined microarray as described in the section on immobilizing capture oligonucleotides.
  • the second step was the addition of about 50 ⁇ l of 10 nM capture ligands having complementary oligonucleotides, prepared as described in the preceding section, in casein buffer to the immobilized capture oligonucleotides in the wells of the microtiter plate.
  • This step was performed under conditions typical for a normal immunoassay binding step (i.e. moderate salt and temperature conditions), partly to protect the structure and integrity of the antibody portion of the conjugate, and partly for ease of use.
  • the third step involved the addition of the specific concentrations of IL-2, IL-8, IL- 12, Interferon-gamma, FGF-basic, and GMCSF antigens to the wells.
  • concentrations of each antigen used in the assay were: 0 pg/ml, 2 pg/ml, 10 pg/ml, 100 pg/ml, 400 pg/ml, and 1000 pg/ml.
  • the added antigen in casein buffer were reacted at 37°C for 1 hour and washed with wash buffer 3 times.
  • the fourth step was the addition of the detector ligands for each antigen, prepared as described in the preceding section, to the wells of the microtiter plate.
  • Figure 6 shows the CCD camera picture illustrating the Cy5.5 emissions from the complementary oligonucleotides on the left side, and PBXL-1 emissions from the bound detector antibodies for IL-2, IL-8, IL-12, Interferon-gamma, FGF-basic, and GMCSF antigens on the right side.
  • the analyte (or antigen) concentration is identified to the right of the picture illustrating the PBXL-1 emissions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un système utile pour des dosages contenant un support solide, une pluralité d'oligonucléotides de capture immobilisés sur le support solide ainsi que des oligonucléotides complémentaires fixés à des ligands de capture. Un marqueur détectable peut être fixé directement aux oligonucléotides de capture ou aux oligonucléotides complémentaires. Les oligonucléotides marqués peuvent être détectés et utilisés afin de déterminer la qualité du dosage. Le ligand détecteur marqué correspondant à un ligand cible peut aussi être détecté indépendamment de l'oligonucléotide marqué.
EP04752910A 2004-05-20 2004-05-20 Systeme de dosage utilisant des oligonucleotides marques Withdrawn EP1766050A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2004/015982 WO2005118855A1 (fr) 2004-05-20 2004-05-20 Systeme de dosage utilisant des oligonucleotides marques

Publications (2)

Publication Number Publication Date
EP1766050A1 true EP1766050A1 (fr) 2007-03-28
EP1766050A4 EP1766050A4 (fr) 2008-03-05

Family

ID=35462918

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04752910A Withdrawn EP1766050A4 (fr) 2004-05-20 2004-05-20 Systeme de dosage utilisant des oligonucleotides marques

Country Status (2)

Country Link
EP (1) EP1766050A4 (fr)
WO (1) WO2005118855A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000079008A2 (fr) * 1999-06-21 2000-12-28 Kris Richard M Systeme d'analyse extremement productif
US20020051974A1 (en) * 1998-11-30 2002-05-02 Dodge Anthony H. Pcr assay
WO2002064825A2 (fr) * 2001-02-14 2002-08-22 Nanogen Recognomics Gmbh Procedes, procedures et supports, permettant l'utilisation de dispositifs microelectroniques a jeux ordonnes d'echantillons pour effectuer des analyses immunologiques en multiplex
US20020146745A1 (en) * 2001-04-03 2002-10-10 Surromed, Inc. Methods and reagents for multiplexed analyte capture, surface array self-assembly, and analysis of complex biological samples
EP1249500A1 (fr) * 2001-04-12 2002-10-16 chimera biotec GmbH Procédé pour la détermination de la concentration d'un analyte
WO2004094668A2 (fr) * 2003-04-18 2004-11-04 Beckman Coulter, Inc. Paires d'oligonucleotides pour immunodetection multiplexee oligonucleotide pairs for multiplexed binding assays
WO2004104230A1 (fr) * 2003-05-16 2004-12-02 Beckman Coulter, Inc. Reduction de la variation d'une analyse par micro-reseau au moyen de taches de reference internes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955268A (en) * 1996-04-26 1999-09-21 Abbott Laboratories Method and reagent for detecting multiple nucleic acid sequences in a test sample

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020051974A1 (en) * 1998-11-30 2002-05-02 Dodge Anthony H. Pcr assay
WO2000079008A2 (fr) * 1999-06-21 2000-12-28 Kris Richard M Systeme d'analyse extremement productif
WO2002064825A2 (fr) * 2001-02-14 2002-08-22 Nanogen Recognomics Gmbh Procedes, procedures et supports, permettant l'utilisation de dispositifs microelectroniques a jeux ordonnes d'echantillons pour effectuer des analyses immunologiques en multiplex
US20020146745A1 (en) * 2001-04-03 2002-10-10 Surromed, Inc. Methods and reagents for multiplexed analyte capture, surface array self-assembly, and analysis of complex biological samples
EP1249500A1 (fr) * 2001-04-12 2002-10-16 chimera biotec GmbH Procédé pour la détermination de la concentration d'un analyte
WO2004094668A2 (fr) * 2003-04-18 2004-11-04 Beckman Coulter, Inc. Paires d'oligonucleotides pour immunodetection multiplexee oligonucleotide pairs for multiplexed binding assays
WO2004104230A1 (fr) * 2003-05-16 2004-12-02 Beckman Coulter, Inc. Reduction de la variation d'une analyse par micro-reseau au moyen de taches de reference internes

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NIEMEYER C M ET AL: "OLIGONUCLEOTIDE-DIRECTED SELF-ASSEMBLY OF PROTEINS: SEMISYNTHETIC DNA-STREPTAVIDIN HYBRID MOLECULES AS CONNECTORS FOR THE GENERATION OF MACROSCOPIC ARRAYS AND THE CONSTRUCTION OF SUPRAMOLECULAR BIOCONJUGATES" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 22, no. 25, January 1994 (1994-01), pages 5530-5539, XP000645135 ISSN: 0305-1048 *
NIEMEYER CHRISTOF M ET AL: "DNA-directed immobilization: Efficient, reversible, and site-selective surface binding of proteins by means of covalent DNA-streptavidin conjugates" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 268, no. 1, 1 March 1999 (1999-03-01), pages 54-63, XP002176566 ISSN: 0003-2697 *
See also references of WO2005118855A1 *

Also Published As

Publication number Publication date
WO2005118855A1 (fr) 2005-12-15
EP1766050A4 (fr) 2008-03-05

Similar Documents

Publication Publication Date Title
US20070243551A1 (en) Assay System Using Labeled Oligonucleotides
US5985548A (en) Amplification of assay reporters by nucleic acid replication
AU597896B2 (en) Method and kit for performing nucleic acid hybridization assays
EP0999285B1 (fr) Methodes et compositions pour l'amplification des signaux detectables en essais a liaisons specifiques
US20030049625A1 (en) Rapid and sensitive proximity-based assay for the detection and quantification of DNA binding proteins
CA2114627A1 (fr) Trousse d'analyse quantitative en phase liquide d'oligonucleotides et methode d'utilisation
EP0405913A2 (fr) Sonde d'acide nucléique hydrophobe
US20180171391A1 (en) Methods and Compositions For Sorting and/or Determining Organisms
EP0436547A4 (en) Process for rapid nucleic acid detection
US20040072176A1 (en) Binding interactions in dipstick assays
EP1476557B1 (fr) Dosage rapide et sensible pour la detection et la quantification de co-regulateurs de facteurs de fixation aux acides nucleiques
US20080254999A1 (en) Linear nucleic acid and sequence therefor
US6399299B1 (en) Amplified array analysis system
JP3340715B2 (ja) 被検体、その相互作用又は反応動力学を定量的又は定性的に測定する方法及びサンプルキャリア
JP2002505846A (ja) シグナル増幅およびプロセッシングのための多重逐次的ポリヌクレオチド置換反応
US20030073091A1 (en) Use of generic oligonucleotide microchips to detect protein-nucleic acid interactions
EP1625233B1 (fr) Reduction de la variation d'une analyse par micro-reseau au moyen de taches de reference internes
WO2005118855A1 (fr) Systeme de dosage utilisant des oligonucleotides marques
KR20040035248A (ko) 단일가닥핵산 어레이를 이용한 특정물질 동정 및 분석방법및 대장균에 대한 핵산 리간드
US8153367B2 (en) Amplified array analysis system
KR20050106759A (ko) 단일가닥핵산의 이중기능을 이용한 특정물질의 동정 및분석방법
US5910410A (en) Dual tag binding assay
US20070037174A1 (en) Chemiluminescent generated fluorescent labeling
JPH09152433A (ja) 固相担体に固定した核酸等の検出方法
JP2002125700A (ja) 二本鎖ｄｎａの分析方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20061219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): DE FR GB IT

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 20080205

17Q First examination report despatched

Effective date: 20080618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20081029